Literature DB >> 26984141

Statin Concentrations Below the Minimum Inhibitory Concentration Attenuate the Virulence of Rhizopus oryzae.

Anne-Pauline Bellanger1, Alexander M Tatara1, Fazal Shirazi1, Teclegiorgis Gebremariam2, Nathaniel D Albert1, Russell E Lewis3, Ashraf S Ibrahim2, Dimitrios P Kontoyiannis1.   

Abstract

BACKGROUND: Mucormycosis is a destructive invasive mold infection afflicting patients with diabetes and hematologic malignancies. Patients with diabetes are often treated with statins, which have been shown to have antifungal properties. We sought to examine the effects of statins on Rhizopus oryzae, a common cause of mucormycosis.
METHODS: Clinical strains of R. oryzae were exposed to lovastatin, atorvastatin, and simvastatin and the minimum inhibitory concentrations (MICs) were determined. R. oryzae germination, DNA fragmentation, susceptibility to oxidative stress, and ability to damage endothelial cells were assessed. We further investigated the impact of exposure to lovastatin on the virulence of R. oryzae
RESULTS: All statins had MICs of >64 µg/mL against R. oryzae Exposure of R. oryzae to statins decreased germling formation, induced DNA fragmentation, and attenuated damage to endothelial cells independently of the expression of GRP78 and CotH. Additionally, R. oryzae exposed to lovastatin showed macroscopic loss of melanin, yielded increased susceptibility to the oxidative agent peroxide, and had attenuated virulence in both fly and mouse models of mucormycosis.
CONCLUSIONS: Exposure of R. oryzae to statins at concentrations below their MICs decreased virulence both in vitro and in vivo. Further investigation is warranted into the use of statins as adjunctive therapy in mucormycosis.
© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.

Entities:  

Keywords:  Rhizopus oryzae; apoptosis; fly model; germination; murine model; statins; virulence

Mesh:

Substances:

Year:  2016        PMID: 26984141      PMCID: PMC5007635          DOI: 10.1093/infdis/jiw090

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  24 in total

1.  The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice.

Authors:  Mingfu Liu; Brad Spellberg; Quynh T Phan; Yue Fu; Yong Fu; Amy S Lee; John E Edwards; Scott G Filler; Ashraf S Ibrahim
Journal:  J Clin Invest       Date:  2010-05-17       Impact factor: 14.808

2.  Future directions in mucormycosis research.

Authors:  Dimitrios P Kontoyiannis; Russell E Lewis; Oliver Lortholary; Oliver Lotholary; Brad Spellberg; Georgios Petrikkos; Emmanuel Roilides; Emmanuel Roillides; Ashraf Ibrahim; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2012-02       Impact factor: 9.079

3.  CotH3 mediates fungal invasion of host cells during mucormycosis.

Authors:  Teclegiorgis Gebremariam; Mingfu Liu; Guanpingsheng Luo; Vincent Bruno; Quynh T Phan; Alan J Waring; John E Edwards; Scott G Filler; Michael R Yeaman; Ashraf S Ibrahim
Journal:  J Clin Invest       Date:  2013-12-20       Impact factor: 14.808

Review 4.  Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.

Authors:  H Lennernäs; G Fager
Journal:  Clin Pharmacokinet       Date:  1997-05       Impact factor: 6.447

5.  Growth inhibition of Candida species and Aspergillus fumigatus by statins.

Authors:  Ian G Macreadie; Georgia Johnson; Tanja Schlosser; Peter I Macreadie
Journal:  FEMS Microbiol Lett       Date:  2006-09       Impact factor: 2.742

6.  Interactions between statins and Penicillium chrysogenum antifungal protein (PAF) to inhibit the germination of sporangiospores of different sensitive Zygomycetes.

Authors:  László Galgóczy; Tamás Papp; Gyöngyi Lukács; Eva Leiter; István Pócsi; Csaba Vágvölgyi
Journal:  FEMS Microbiol Lett       Date:  2007-02-16       Impact factor: 2.742

7.  Lovastatin triggers an apoptosis-like cell death process in the fungus Mucor racemosus.

Authors:  L V Roze; J E Linz
Journal:  Fungal Genet Biol       Date:  1998-11       Impact factor: 3.495

8.  Decrease in the number of reported cases of zygomycosis among patients with diabetes mellitus: a hypothesis.

Authors:  Dimitrios P Kontoyiannis
Journal:  Clin Infect Dis       Date:  2007-03-02       Impact factor: 9.079

9.  Of mice, flies--and men? Comparing fungal infection models for large-scale screening efforts.

Authors:  Sascha Brunke; Jessica Quintin; Lydia Kasper; Ilse D Jacobsen; Martin E Richter; Ekkehard Hiller; Tobias Schwarzmüller; Christophe d'Enfert; Karl Kuchler; Steffen Rupp; Bernhard Hube; Dominique Ferrandon
Journal:  Dis Model Mech       Date:  2015-03-18       Impact factor: 5.758

10.  The effects of statins on the mevalonic acid pathway in recombinant yeast strains expressing human HMG-CoA reductase.

Authors:  Agata Maciejak; Agata Leszczynska; Ilona Warchol; Monika Gora; Joanna Kaminska; Danuta Plochocka; Monika Wysocka-Kapcinska; Dorota Tulacz; Joanna Siedlecka; Ewa Swiezewska; Maciej Sojka; Witold Danikiewicz; Norbert Odolczyk; Anna Szkopinska; Grazyna Sygitowicz; Beata Burzynska
Journal:  BMC Biotechnol       Date:  2013-08-30       Impact factor: 2.563

View more
  7 in total

1.  Lichtheimia corymbifera Colonization Leading to Pulmonary Infection Can Be Prevented with Liposomal Amphotericin B in a New Murine Model.

Authors:  Thomas Brunet; Kévin Brunet; Grégory Jouvion; Estelle Cateau; Sandrine Marchand; Blandine Rammaert
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

2.  Innate immunity in fungi: Is regulated cell death involved?

Authors:  Maria Laura Gaspar; Teresa E Pawlowska
Journal:  PLoS Pathog       Date:  2022-05-19       Impact factor: 6.823

3.  Mucormycosis in renal transplant recipients: review of 174 reported cases.

Authors:  Yan Song; Jianjun Qiao; Gaffi Giovanni; Guangjun Liu; Hao Yang; Jianyong Wu; Jianghua Chen
Journal:  BMC Infect Dis       Date:  2017-04-18       Impact factor: 3.090

Review 4.  Therapy of Mucormycosis.

Authors:  Nikolaos V Sipsas; Maria N Gamaletsou; Amalia Anastasopoulou; Dimitrios P Kontoyiannis
Journal:  J Fungi (Basel)       Date:  2018-07-31

Review 5.  Combination therapy in Mucormycosis: Current evidence from the world literature, a mini review.

Authors:  Durga Shankar Meena; Deepak Kumar; Gopal Krishana Bohra
Journal:  J Mycol Med       Date:  2022-09-14       Impact factor: 3.746

Review 6.  COVID-19-Associated Mucormycosis: A Matter of Concern Amid the SARS-CoV-2 Pandemic.

Authors:  Pankaj Chandley; Priyanka Subba; Soma Rohatgi
Journal:  Vaccines (Basel)       Date:  2022-08-06

7.  In Vitro Activity of Amphotericin B in Combination with Statins against Clinical and Environmental Rhizopus oryzae Strains.

Authors:  Mahsa Naeimi Eshkaleti; Parivash Kordbacheh; Seyed Jamal Hashemi; Mehraban Falahati; Farideh Zaini; Hossein Mirhendi; Mahin Safara; Leila Hosseinpoor
Journal:  Iran J Public Health       Date:  2019-05       Impact factor: 1.429

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.